Gulf International Bank UK Ltd Trims Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Gulf International Bank UK Ltd cut its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 9.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,137 shares of the medical instruments supplier’s stock after selling 618 shares during the quarter. Gulf International Bank UK Ltd’s holdings in West Pharmaceutical Services were worth $2,160,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of WST. Sunbelt Securities Inc. acquired a new stake in shares of West Pharmaceutical Services during the 1st quarter worth approximately $25,000. RVW Wealth LLC acquired a new stake in shares of West Pharmaceutical Services during the 3rd quarter worth approximately $38,000. First Horizon Advisors Inc. grew its stake in shares of West Pharmaceutical Services by 37.4% during the 1st quarter. First Horizon Advisors Inc. now owns 147 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 40 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of West Pharmaceutical Services during the 3rd quarter worth approximately $53,000. Finally, Addison Advisors LLC grew its stake in shares of West Pharmaceutical Services by 37.9% during the 3rd quarter. Addison Advisors LLC now owns 142 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 39 shares during the period. 91.23% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Stock Performance

NYSE WST opened at $395.89 on Friday. The company has a market cap of $28.98 billion, a P/E ratio of 50.24, a P/E/G ratio of 7.05 and a beta of 1.03. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.88 and a quick ratio of 2.24. The stock has a 50-day moving average of $370.68 and a two-hundred day moving average of $364.29. West Pharmaceutical Services, Inc. has a 1-year low of $310.42 and a 1-year high of $415.73.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last released its earnings results on Thursday, February 15th. The medical instruments supplier reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.78 by $0.05. West Pharmaceutical Services had a return on equity of 21.60% and a net margin of 20.12%. The company had revenue of $732.00 million during the quarter, compared to the consensus estimate of $740.43 million. During the same period in the previous year, the company posted $1.77 EPS. West Pharmaceutical Services’s revenue was up 3.3% compared to the same quarter last year. As a group, analysts anticipate that West Pharmaceutical Services, Inc. will post 7.62 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Wednesday, April 24th will be given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.20%. The ex-dividend date of this dividend is Tuesday, April 23rd. West Pharmaceutical Services’s dividend payout ratio is presently 10.15%.

Insider Transactions at West Pharmaceutical Services

In related news, CAO Chad Winters sold 815 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $358.82, for a total value of $292,438.30. Following the completion of the transaction, the chief accounting officer now directly owns 1,309 shares of the company’s stock, valued at $469,695.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, VP Charles Witherspoon sold 2,019 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $358.62, for a total value of $724,053.78. Following the completion of the transaction, the vice president now directly owns 1,979 shares of the company’s stock, valued at $709,708.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Chad Winters sold 815 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $358.82, for a total value of $292,438.30. Following the completion of the sale, the chief accounting officer now owns 1,309 shares of the company’s stock, valued at approximately $469,695.38. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 73,978 shares of company stock valued at $26,653,772. 1.13% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on WST shares. UBS Group dropped their price objective on shares of West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating on the stock in a research note on Friday, February 16th. KeyCorp raised their price objective on West Pharmaceutical Services from $440.00 to $470.00 and gave the company an “overweight” rating in a report on Tuesday, February 13th. StockNews.com lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Friday, February 16th. Finally, Jefferies Financial Group upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and raised their price objective for the company from $323.00 to $536.00 in a report on Wednesday, February 7th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $435.20.

Check Out Our Latest Stock Report on West Pharmaceutical Services

About West Pharmaceutical Services

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Featured Stories

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTFree Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.